Plans are being finalized for the next clinical trial, which could be a combination study of MB07133, a cytotoxic agent with sorafenib (Nexavar), a cytostatic agent.
Phase of Trial: Phase I/II
Latest Information Update: 12 Nov 2007
At a glance
- Drugs MB 7133; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Metabasis Therapeutics
- 12 Nov 2007 New trial record.